Literature DB >> 26640291

Risk-reducing Surgery in Women at Risk for Familial Breast or Ovarian Cancer.

K Rhiem1, K Pfeifer2, R K Schmutzler1, M Kiechle2.   

Abstract

An estimated 5 % of breast cancers and 10 % of ovarian cancers may be due to inherited autosomal dominant breast and ovarian cancer alleles BRCA1 und BRCA2. According to population-based studies 1 or 2 women per 1000 carry such a risk allele. The cumulative cancer risk for healthy women with a BRCA-mutation is between 60 and 85 % for breast cancer and between 20 and 60 % for ovarian cancer. Recent studies have reported an increased risk for contralateral breast cancer in women after unilateral breast cancer. Since 1997 the German Cancer Aid has supported an interdisciplinary approach for high-risk women consisting of genetic testing, counselling and prevention in 12 specialised centres. Since 2005 this concept has received additional support from health insurance companies, and results have been assessed with regard to outcomes (e.g. reduced mortality due to more intensive early diagnosis). The number of centres has increased to 15 at various university hospitals. These interdisciplinary centres offer women the opportunity to participate in a structured screening programme for the early diagnosis of breast cancer and provide non-directive counselling on the options for risk-reducing surgery, e.g., prophylactic bilateral salpingo-oophorectomy, prophylactic bilateral mastectomy or contralateral prophylactic mastectomy after unilateral breast cancer. Such surgical interventions can significantly reduce the risk of disease, the respective disease-specific mortality and - particularly prophylactic bilateral salpingo-oophorectomy - total mortality in BRCA-mutation carriers.

Entities:  

Keywords:  BRCA; breast; breast cancer; genetics; gynaecology; ovary

Year:  2012        PMID: 26640291      PMCID: PMC4651164          DOI: 10.1055/s-0032-1315362

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  20 in total

1.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  H Meijers-Heijboer; B van Geel; W L van Putten; S C Henzen-Logmans; C Seynaeve; M B Menke-Pluymers; C C Bartels; L C Verhoog; A M van den Ouweland; M F Niermeijer; C T Brekelmans; J G Klijn
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

2.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.

Authors:  Alfons Meindl; Heide Hellebrand; Constanze Wiek; Verena Erven; Barbara Wappenschmidt; Dieter Niederacher; Marcel Freund; Peter Lichtner; Linda Hartmann; Heiner Schaal; Juliane Ramser; Ellen Honisch; Christian Kubisch; Hans E Wichmann; Karin Kast; Helmut Deissler; Christoph Engel; Bertram Müller-Myhsok; Kornelia Neveling; Marion Kiechle; Christopher G Mathew; Detlev Schindler; Rita K Schmutzler; Helmut Hanenberg
Journal:  Nat Genet       Date:  2010-04-18       Impact factor: 38.330

3.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

4.  Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  Kelly Metcalfe; Henry T Lynch; Parviz Ghadirian; Nadine Tung; Ivo Olivotto; Ellen Warner; Olufunmilayo I Olopade; Andrea Eisen; Barbara Weber; Jane McLennan; Ping Sun; William D Foulkes; Steven A Narod
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

5.  Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.

Authors:  Angela Chetrit; Galit Hirsh-Yechezkel; Yehuda Ben-David; Flora Lubin; Eitan Friedman; Siegal Sadetzki
Journal:  J Clin Oncol       Date:  2008-01-01       Impact factor: 44.544

6.  Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.

Authors:  Susan M Domchek; Tara M Friebel; Susan L Neuhausen; Theresa Wagner; Gareth Evans; Claudine Isaacs; Judy E Garber; Mary B Daly; Rosalind Eeles; Ellen Matloff; Gail E Tomlinson; Laura Van't Veer; Henry T Lynch; Olufunmilayo I Olopade; Barbara L Weber; Timothy R Rebbeck
Journal:  Lancet Oncol       Date:  2006-03       Impact factor: 41.316

7.  BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.

Authors:  Marie Soegaard; Susanne Kruger Kjaer; Mark Cox; Eva Wozniak; Estrid Høgdall; Claus Høgdall; Jan Blaakaer; Ian J Jacobs; Simon A Gayther; Susan J Ramus
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

8.  Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.

Authors:  Noah D Kauff; Susan M Domchek; Tara M Friebel; Mark E Robson; Johanna Lee; Judy E Garber; Claudine Isaacs; D Gareth Evans; Henry Lynch; Rosalind A Eeles; Susan L Neuhausen; Mary B Daly; Ellen Matloff; Joanne L Blum; Paul Sabbatini; Richard R Barakat; Clifford Hudis; Larry Norton; Kenneth Offit; Timothy R Rebbeck
Journal:  J Clin Oncol       Date:  2008-02-11       Impact factor: 44.544

9.  Pathology of ovarian cancers in BRCA1 and BRCA2 carriers.

Authors:  Sunil R Lakhani; Sanjiv Manek; Frederique Penault-Llorca; Adrienne Flanagan; Laurent Arnout; Samantha Merrett; Lesley McGuffog; Dawn Steele; Peter Devilee; Jan G M Klijn; Hanne Meijers-Heijboer; Paolo Radice; Silvana Pilotti; Heli Nevanlinna; Ralf Butzow; Hagay Sobol; Jocylyne Jacquemier; Dominique Stoppa Lyonet; Susan L Neuhausen; Barbara Weber; Teresa Wagner; Robert Winqvist; Yves-Jean Bignon; Franco Monti; Fernando Schmitt; Gilbert Lenoir; Susanne Seitz; Ute Hamman; Paul Pharoah; Geoff Lane; Bruce Ponder; D Timothy Bishop; Douglas F Easton
Journal:  Clin Cancer Res       Date:  2004-04-01       Impact factor: 12.531

10.  The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.

Authors:  Kerstin Rhiem; Christoph Engel; Monika Graeser; Silke Zachariae; Karin Kast; Marion Kiechle; Nina Ditsch; Wolfgang Janni; Christoph Mundhenke; Michael Golatta; Dominic Varga; Sabine Preisler-Adams; Tilman Heinrich; Ulrich Bick; Dorothea Gadzicki; Susanne Briest; Alfons Meindl; Rita K Schmutzler
Journal:  Breast Cancer Res       Date:  2012-12-07       Impact factor: 6.466

View more
  3 in total

1.  Small Cell Ovarian Carcinomas - Characterisation of Two Rare Tumor Entities.

Authors:  K Münstedt; R Estel; T Dreyer; A Kurata; A Benz
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-07       Impact factor: 2.915

2.  Participation in the SUCCESS-A Trial Improves Intensity and Quality of Care for Patients with Primary Breast Cancer.

Authors:  U Andergassen; N S Kasprowicz; P Hepp; C Schindlbeck; N Harbeck; M Kiechle; H Sommer; M W Beckmann; K Friese; W Janni; B Rack; C Scholz
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-01       Impact factor: 2.915

3.  Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy.

Authors:  Michael G Schrauder; Lisa Brunel-Geuder; Lothar Häberle; Marius Wunderle; Juliane Hoyer; Roland Csorba; André Reis; Rüdiger Schulz-Wendtland; Matthias W Beckmann; Michael P Lux
Journal:  Eur J Med Res       Date:  2019-09-14       Impact factor: 2.175

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.